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| INTRODUCTION
Malignant glioma, glioblastoma (GBM), is a very aggressive and common form of primary brain cancer in adults with a median survival of less than 15 months. 1 Chondroitin sulfate proteoglycans (CSPGs), such as membrane-associated CSPG4/NG2, PTPRZ1 and CD44, as well as the lectican family members versican, aggrecan and brevican, are frequently overexpressed in glioma and have been implicated in glioma cell growth, vascularization and invasion. 2, 3 Although several studies have demonstrated a functional role for the CS segments of CSPGs in glioma progression in vitro, 4, 5 their significance in blocking the penetration of chemotherapeutics, such as temozolomide (TMZ), and/or role in promoting resistance has not been investigated.
Chase ABC I (Chase) is a bacterial enzyme that depolymerizes a variety of CS glucosaminoglycan (GAG) chains, which are covalently attached to the CSPG core protein, without altering the core protein structure. 6 Previous work from our laboratory indicated that degradation of the glioma extracellular matrix (ECM) with an oncolytic virus (OV) expressing the Chase bacterial enzyme enhanced OV spread and anti-tumor efficacy both in vitro and in vivo. 7, 8 The recent molecular characterization of Chase has revealed several potential glycosylation sites in the enzyme that can limit enzymatic function and/or secretion in mammalian cells. 9 In the present study, using site-directed mutagenesis of several potential glycosylation sites, we generated a humanized mutant Chase (ChaseM) enzyme that results in optimal enzymatic expression and function in mammalian cells. We have also generated an OV expressing the ChaseM enzyme and determined its effects on glioma cells in combination with TMZ. With the recent Food and Drug Administration approval of the T-Vec oncolytic HSV for nonresectable melanoma, there is new hope for such novel treatment modalities for GBM patients. 10, 11 We hypothesized that disruption of cell-cell or cell-ECM interactions with a humanized chondroitinase ABC (ChaseM) enzyme will enhance glioma cell chemotherapeutic availability and sensitivity.
Utilizing patient-derived neurospheres, we found that ChaseM decreases glioma neurosphere aggregation in vitro, akin to the phenotype observed with pharmacologic blockade of CSPG assembly. 
| MATERIALS AND METHODS

| Cells lines and reagents
Human glioma cells (U87ΔEGFR, LN229, Gli36ΔEGFR-H2B-RFP, U251) and Vero cells were cultured as described previously. 7 Primary glioblastoma-derived cells (GB9, GB9-GFP and GBM30) were generated at The Ohio State University or kindly provided by the Mayo Clinic (X12) and maintained in neurosphere cultures as described previously. 7, 12 Cos-7 cells were purchased from the ATCC (Manassas, CA, USA) was used to probe for Chase functionality. Trypan blue exclusion using the Cell Countess (Life Technologies, Inc., Carlsbad, CA, USA) was used to determine glioma cell proliferation.
| ChaseM generation and viruses
Cloning and construction of wild-type Chase ABC has been described previously. 7 Primers G1, G2, G3 and G5, as described previously, 9 were used to mutate the selected N-glycosylation sites of chondroitinase ABC I cDNA using the QuickChange Lightning Multi 
| Animal studies
All murine studies were housed and handled in accordance with the 
| Statistical analysis
| OV with a functional ChaseM enzyme enhances viral spread and glioma cell killing
We have previously described the ability of Chase to enhance OV spread in glioma neurospheres. 7 To determine whether the humanization of ChaseM could enhance the anti-glioma efficacy of a herpes simplex I (HSV-1) OV, we generated a novel ChaseM expressing OV (OV-ChaseM) (see Supporting information, Figure S2 ). 7 Primary GBM neurosphere derived cells were infected with the indicated virus and 
| OV-ChaseM enhances TMZ induced apoptotic cell killing of glioma neurospheres
Because a diminished capacity to form aggregates implied a decreased physical barrier for the spread of chemotherapeutic drugs, 7,18,19 we postulated that ChaseABC would be an effective therapeutic modality All experiments were performed in triplicate with at least three independent replicates groups (p < 0.0001) ( Figure 4A ). Additionally, specific examination of glioma cell death using a live/dead cell stain also revealed a significant induction of cell death following OV-ChaseM plus TMZ treatment (p < 0.0001) ( Figure 4B ). Using a two-way ANOVA model to test for synergistic interactions, we determined that there was a significant and synergistic interaction between OV-ChaseM and TMZ resulting in the induction of glioma cell death (p < 0.002). Taken together, these data indicate the induction of apoptosis observed following TMZ treatment is significantly enhanced by OV infection, with maximal sensitivity observed using an OV expressing the ChaseM enzyme.
| OV-ChaseM plus TMZ inhibits pro-survival AKT responses in glioma neurospheres
The marked increase in glioma neurosphere apoptosis and cell death led us to further interrogate the cellular signaling alterations that occur following OV-ChaseM plus TMZ treatment. AKT, a serine/threonine kinase that is central to the RTK/PTEN/PI3K pathway, plays a critical role in cancer cell growth and survival. 20 Moreover, AKT activation, via phosphorylation at Serine473, is associated with TMZ chemoresistance in glioblastoma cells. 21 Therefore, we next examined Figure 4C and the mean from three independent experiments normalized to untreated cells is quantified in Figure 4D . Moreover, there was a significant synergistic interaction of OV-ChaseM and TMZ in the reduction of pAKT levels (p < 0.008). This pAKT inhibition mediated by combinatorial therapy indicated that OV-ChaseM infection sensitized glioma neurospheres to TMZ, making them more susceptible to its chemotherapeutic, anticancer effects.
3.6 | OV-ChaseM plus TMZ combinatorial therapy enhances survival in vivo have all been reported to be widely expressed in human GBMs. 3 Previous studies also provide strong evidence for the ability of PTPRZ1
to drive glioma cell growth, migration and invasion in vitro and in vivo. 24, 25 CS chain interactions in CD44 are known to be significant in the CD44 mediated cell-cell interactions 26 and their disruption has been shown to inhibit the growth of melanoma in mice. [27] [28] [29] Similarly, NG2 blocking antibodies led to a reduction in tumor growth and proliferation in vivo, as well as enhanced sensitivity to various chemotherapeutic agents. [30] [31] [32] [33] These studies highlight the importance and potential therapeutic targeting of CSPGs in cancer therapy. In the present study, a drastic reduction in glioma cell aggregation was observed following humanized ChaseM transfection and OV-ChaseM infection.
Although the neurosphere formation to anti-cancer drugs is a strong prognostic indicator for the effectiveness of chemotherapy, 19 in vitro treatment with Chase ABC did not affect glioma cell viability or proliferation, implying that, although CS chains on CSPG were important for aggregation, their removal did not affect glioma cell viability. Because cell-cell interactions have been implicated in resistance to chemotherapy and apoptosis, 34 the disruption of these interactions using OV-ChaseM enhanced glioma cell killing by TMZ. In corroboration with previous studies, 35 we observed a significant and 
